Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE
The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.
Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.
An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.
Research in Review
A study of the biologic drug ustekinumab has found it to be a better treatment for psoriasis than tumor necrosis factor-alpha (TNF-α) inhibitors.
Guidelines for rheumatoid arthritis formulated by a panel of patients had most of the same recommendations as those developed by a panel of physicians.